CNTX
Context Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CNTX
Context Therapeutics Inc.
A biopharmaceutical company focused on developing hormone therapies for cancer treatment
2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103
--
Context Therapeutics Inc., was incorporated in Delaware in April 2015. It is a clinical-stage biopharmaceutical company dedicated to improving the lives of women suffering from cancer. Far-reaching advances in oncology drug development have expanded the treatment options available to women with cancer, but treatment resistance and recurrence continue to limit the efficacy and duration of such treatments.
Company Financials
EPS
CNTX has released its 2025 Q3 earnings. EPS was reported at -0.1, versus the expected -0.09, missing expectations. The chart below visualizes how CNTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
